Abstract
This review mainly covers last five year literature on CCK1R agonists and antagonists. These CCK1R ligands have been found following the two usual and complementary strategies for drug discovery: rational design based on structure activity relationships on the CCK-7 and CCK-4 peptide sequences of the endogenous ligands and random screening of diverse compounds, followed by hit optimization. The first group includes: chimeric bifunctional opioid/CCK peptides, designed as opioid agonists with balanced CCK1R/CCK2R antagonist activity for the treatment of neuropathic pain, antagonist and agonist dipeptoids, and 1,3-dioxoperhydropyrido[1,2-c]pyrimidine- and anthranilic acidbased antagonists. Among the ligands derived from random screening, a few new 1,4-benzodiazepine-, 1,5- benzodiazepine-, and five member ring heterocycle-based CCK1R ligands have been reported. Finally, taking into account the importance of receptor mapping studies for ligand optimization and future precise de novo receptor structurebased design of new selective and more effective ligands, the most significant conclusions of these studies have also been reviewed.
Keywords: CCK1R ligands, peptidomimetics, Dipeptoids, Anthranilic Acid, 1,5-benzodiazepine
Current Topics in Medicinal Chemistry
Title: Strategies for Design of Non Peptide CCK1R Agonist/Antagonist Ligands
Volume: 7 Issue: 12
Author(s): M. Teresa Garcia-Lopez, Rosario Gonzalez-Muniz, Mercedes Martin-Martinez and Rosario Herranz
Affiliation:
Keywords: CCK1R ligands, peptidomimetics, Dipeptoids, Anthranilic Acid, 1,5-benzodiazepine
Abstract: This review mainly covers last five year literature on CCK1R agonists and antagonists. These CCK1R ligands have been found following the two usual and complementary strategies for drug discovery: rational design based on structure activity relationships on the CCK-7 and CCK-4 peptide sequences of the endogenous ligands and random screening of diverse compounds, followed by hit optimization. The first group includes: chimeric bifunctional opioid/CCK peptides, designed as opioid agonists with balanced CCK1R/CCK2R antagonist activity for the treatment of neuropathic pain, antagonist and agonist dipeptoids, and 1,3-dioxoperhydropyrido[1,2-c]pyrimidine- and anthranilic acidbased antagonists. Among the ligands derived from random screening, a few new 1,4-benzodiazepine-, 1,5- benzodiazepine-, and five member ring heterocycle-based CCK1R ligands have been reported. Finally, taking into account the importance of receptor mapping studies for ligand optimization and future precise de novo receptor structurebased design of new selective and more effective ligands, the most significant conclusions of these studies have also been reviewed.
Export Options
About this article
Cite this article as:
M. Teresa Garcia-Lopez , Rosario Gonzalez-Muniz , Mercedes Martin-Martinez and Rosario Herranz , Strategies for Design of Non Peptide CCK1R Agonist/Antagonist Ligands, Current Topics in Medicinal Chemistry 2007; 7 (12) . https://dx.doi.org/10.2174/156802607780960537
DOI https://dx.doi.org/10.2174/156802607780960537 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Heat Shock Proteins (HSPs) Based Anti-Cancer Vaccines
Current Molecular Medicine Engineered Nanoparticles for Improved Vasoactive Intestinal Peptide (VIP) Biomedical Applications
Recent Patents on Nanomedicine Promotion of Cortico-Cerebral Precursors Expansion by Artificial pri-miRNAs Targeted Against the Emx2 Locus
Current Gene Therapy Gallium in Cancer Treatment
Current Topics in Medicinal Chemistry Celastrol Inhibits the Proliferation and Decreases Drug Resistance of Cisplatin- Resistant Gastric Cancer SGC7901/DDP Cells
Anti-Cancer Agents in Medicinal Chemistry An Overview on the Role of miR-451 in Lung Cancer: Diagnosis, Therapy, and Prognosis
MicroRNA The Anticancer Properties of Silibinin: Its Molecular Mechanism and Therapeutic Effect in Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Interactions of the Aryl Hydrocarbon Receptor with Inflammatory Mediators:Beyond CYP1A Regulation
Current Drug Metabolism Epigenetic Variation and Customising Nutritional Intervention
Current Pharmacogenomics and Personalized Medicine Metabolomics as a Functional Tool in Screening Gastro Intestinal Diseases: Where are we in High Throughput Screening?
Combinatorial Chemistry & High Throughput Screening Estrogens as Potential Therapeutic Agents in Multiple Sclerosis
Central Nervous System Agents in Medicinal Chemistry In Vitro Regulatory Effect of Epididymal Serpin CRES on Protease Activity of Proprotein Convertase PC4/PCSK4
Current Molecular Medicine The Histone Deacetylase Inhibitor, MS-275 (Entinostat), Downregulates c-FLIP, Sensitizes Osteosarcoma Cells to FasL, and Induces the Regression of Osteosarcoma Lung Metastases
Current Cancer Drug Targets Recent Insights into COVID-19 in Children and Clinical Recommendations
Current Pediatric Reviews Combinatorial Therapies for Cardiac Regeneration
Recent Patents on Regenerative Medicine Therapeutic Antibodies
Current Molecular Medicine Molecular Imaging: Translation from Rats to Dogs and Humans
Current Medical Imaging Estrogen Receptor Signaling: Impact on Cell Functions
Current Signal Transduction Therapy Cell-Penetrating Peptide-Mediated Topical Delivery of Biomacromolecular Drugs
Current Pharmaceutical Biotechnology State of Art and Recent Developments of Anti-Cancer Strategies Based on TRAIL
Recent Patents on Anti-Cancer Drug Discovery